Back to Journals » Cancer Management and Research » Volume 12

CD56 Expression Is Associated with Biological Behavior of Pancreatic Neuroendocrine Neoplasms

Authors Chen X, Guo C, Cui W, Sun K, Wang Z, Chen X

Received 16 February 2020

Accepted for publication 20 May 2020

Published 17 June 2020 Volume 2020:12 Pages 4625—4631

DOI https://doi.org/10.2147/CMAR.S250071

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Eileen O'Reilly


Xin Chen,1 Chuangen Guo,2 Wenjing Cui,1 Ke Sun,3 Zhongqiu Wang,1 Xiao Chen1

1Department of Radiology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 2100029, People’s Republic of China; 2Department of Radiology, The First Affiliated Hospital, College of Medicine Zhejiang University, Hangzhou 310003, People’s Republic of China; 3Department of Pathology, The First Affiliated Hospital, College of Medicine Zhejiang University, Hangzhou 310003, People’s Republic of China

Correspondence: Zhongqiu Wang; Xiao Chen Tel +086-025-86619843
; +086-025-86617141
Email zhqwang001@126.com; chxwin@163.com

Purpose: CD56 is a neural cell adhesion molecule that plays a role in the cohesiveness of neuroendocrine cells. The aim of this study was to explore the biological values of CD56 expression in pancreatic neuroendocrine neoplasms (PNENs) and its role in predicting PNENs grades.
Patients and Methods: A total of 138 patients with histological-proven PNENs was included (66 G1, 46 G2 and 26 G3). The clinicopathological characteristics, including mitosis count, ki67 index, chromogranin A (CgA), synaptophysin (Syn) and CD56 expression, were evaluated. We assessed the diagnostic performance of markers in predicting PNEN G3 and the association between CD56 expression and risk of G3 or organs invasion.
Results: Lack of CD56 immunoreaction (CD56-) was more common in PNEN G3 than G1/G2 (31% vs 0– 2%, p < 0.01). The sizes of CD56- tumors were larger than CD56 positive tumors in PNEN G3 (p < 0.01). The odds ratio (OR) of CD56- expression was 13.6 [95% confidence interval (CI): 2.1– 88.1] in predicting PNEN G3. The OR of CD56- expression was 6.5 (95% CI: 1.1– 38.6) and 31.9 (95% CI: 1.09– 938.3) in predicting organs invasion and neuroendocrine carcinoma in PNEN G3, respectively. Tumor size (area under the curve [AUC] = 0.77 and size+CD56- expression [AUC = 0.84]) had acceptable performance in predicating PNEN G3.
Conclusion: Lack of CD56 immunoreaction may be a predictor and biological behavior marker for PNEN G3.

Keywords: pancreatic neuroendocrine neoplasm, grade, pancreatic neuroendocrine carcinoma, CD56

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]